Recursion Pharmaceuticals, Inc. develops investigational medicines as a clinical-stage TechBio company using the Recursion OS, an AI-native drug discovery and development platform that integrates biology, chemistry, automation, data science and clinical development. Company updates center on wholly owned and partnered programs in oncology, rare disease, neuroscience, immunology and other therapeutic areas.
Recurring announcements cover clinical and preclinical pipeline progress, financial results, platform infrastructure, automated laboratory operations, collaborations and partner milestones. Recursion also reports governance and leadership changes, investor-conference participation and updates tied to named programs such as REC-1245, REC-4881 and REC-4539 when those programs advance through development.
Recursion (NASDAQ: RXRX) announced significant growth and collaborations in its press release on March 23, 2022. The company partnered with Roche and Genentech to develop up to 40 novel medicines, with an upfront payment of $150 million. Recursion expanded its collaboration with Bayer to explore over a dozen fibrosis programs. Additionally, the company initiated its Phase 2 clinical trial for CCM and advanced various oncology therapeutics. Financially, Recursion reported a net loss of $64.9 million for Q4 2021, a significant increase from the previous year.
Recursion (NASDAQ: RXRX) has achieved a significant milestone by enrolling the first patient in its Phase 2 SYCAMORE clinical trial for REC-994, a novel small molecule aimed at treating cerebral cavernous malformation (CCM). CCM affects approximately 360,000 symptomatic patients in the U.S. and EU5. The trial is a multi-center, randomized, double-blind study expected to enroll around 60 subjects, focusing on the safety, efficacy, and pharmacokinetics of REC-994. This marks the first industry-sponsored human efficacy trial for CCM, highlighting the urgent need for effective therapies in this patient population.
Recursion (NASDAQ: RXRX) updated its clinical trial guidance, including a significant delay for a Phase 2 trial of REC-3599 in Tay-Sachs disease, now expected to start in approximately two years. However, the company is on track for several other trials: REC-994 for Cerebral Cavernous Malformation, REC-2282 for Neurofibromatosis Type 2, and REC-4881 for Familial Adenomatous Polyposis, with expected patient enrollment in Q2 2022. Preparations for a Phase 1 study of REC-3964 in recurrent C. difficile colitis are also proceeding as planned, aiming for enrollment in the second half of 2022.
Recursion (NASDAQ: RXRX), a biotechnology firm focused on drug discovery, announced its participation in two major investor conferences:
- KeyBanc Capital Markets Emerging Technology Summit — March 8-9, 2022
- SVB Leerink Mountain Meeting — March 20-23, 2022
Webcasts will be accessible via the investor section on their website. Recursion utilizes advanced technologies to enhance drug discovery, boasting one of the largest biological datasets and powerful computational resources, aiming to revolutionize medicine.
Recursion (NASDAQ: RXRX) has announced its participation in the upcoming SVB Leerink 11th Annual Global Healthcare Conference from February 14 to February 18, 2022. The conference will feature webcasts accessible in the investor section of www.Recursion.com.
Recursion is a clinical-stage biotechnology firm that focuses on industrializing drug discovery by decoding biology, leveraging its extensive datasets and advanced machine-learning algorithms.
Recursion (NASDAQ: RXRX) announced an expanded collaboration with Bayer AG focusing on fibrosis. The partnership will leverage Recursion's inferential search capabilities to accelerate drug discovery and development in fibrotic diseases, increasing the total number of relevant programs to over a dozen. Each program could yield more than $100 million in milestone payments plus royalties. This collaboration builds on successful prior efforts, with Recursion aiming to operationalize drug discovery more efficiently.
Recursion (NASDAQ: RXRX) announced the appointment of three experts to strengthen its neuroscience focus: Tim Ahfeldt as Fellow, Neuroscience; Irit Rappley as VP, Neuroscience and Translational Research; and Glenn Morrison as VP, Clinical Development. These hires aim to enhance the industrialization of iPSC-derived neural cell types, advance CNS-targeted therapeutics, and propel existing programs through clinical development. The move addresses significant unmet needs in brain disease therapies, leveraging machine learning for novel drug discovery.
Recursion (RXRX) reported its Q3 2021 results, highlighting progress in drug discovery through its Recursion Map and an expanding clinical portfolio. The company is preparing to initiate Phase 2 and Phase 2/3 studies for four clinical programs in early 2022. Financially, Recursion ended Q3 with $578.9 million in cash and reported $2.5 million in revenue, up from $1.0 million in Q3 2020. However, R&D expenses rose to $33.2 million and general administrative costs increased to $15.7 million, leading to a net loss of $47.4 million, compared to $23.9 million a year prior.
Recursion (NASDAQ: RXRX) announced FDA Fast Track designation for REC-2282, an oral small molecule HDAC inhibitor targeting NF2-mutated meningiomas. This designation accelerates drug review for unmet medical needs. REC-2282 aims to benefit neurofibromatosis type-2 patients, with enrollment in a Phase 2/3 study expected to start early next year. Over 34,000 sporadic meningiomas are diagnosed annually in the U.S., with a significant portion driven by NF2 mutations, highlighting an urgent medical need for effective therapies.
BioHive has appointed Katelin Roberts as its full-time Executive Director, effective immediately, after serving in an interim capacity since its launch. BioHive aims to enhance Utah's growing life sciences industry. Roberts, previously CEO of Line Logic, brings extensive leadership experience. BioHive comprises over 1,100 companies in Utah's life sciences sector, employing over 130,000 individuals. The organization focuses on innovation and collaboration to strengthen the state's economy and improve patient outcomes.